Bortezomib (Velcade): A First-in-Class Proteasome Inhibitor

Donald S. Matteson, Ender Erdik, Epimerization of .alpha.-chloroboronic esters by lithium and zinc chlorides Organometallics. ,vol. 2, pp. 1083- 1088 ,(1983) , 10.1021/OM50003A004

M. Bogyo, J. S. McMaster, M. Gaczynska, D. Tortorella, A. L. Goldberg, H. Ploegh, Covalent modification of the active site threonine of proteasomal β subunits and the Escherichia coli homolog HslV by a new class of inhibitors Proceedings of the National Academy of Sciences of the United States of America. ,vol. 94, pp. 6629- 6634 ,(1997) , 10.1073/PNAS.94.13.6629

Donald S. Matteson, Debesh Majumdar, .alpha.-Chloro boronic esters from homologation of boronic esters Journal of the American Chemical Society. ,vol. 102, pp. 7588- 7590 ,(1980) , 10.1021/JA00545A045

Donald S. Matteson, Rahul Ray, Directed chiral synthesis with pinanediol boronic esters Journal of the American Chemical Society. ,vol. 102, pp. 7590- 7591 ,(1980) , 10.1021/JA00545A046

J. Albanell, J. Adams, Bortezomib, a proteasome inhibitor, in cancer therapy: from concept to clinic Drugs of The Future. ,vol. 27, pp. 1079- 1092 ,(2002) , 10.1358/DOF.2002.027.11.697067

Julian Adams, The development of proteasome inhibitors as anticancer drugs. Cancer Cell. ,vol. 5, pp. 417- 421 ,(2004) , 10.1016/S1535-6108(04)00120-5

Reinhard Knorr, Arnold Trzeciak, Willi Bannwarth, Dieter Gillessen, New coupling reagents in peptide chemistry Tetrahedron Letters. ,vol. 30, pp. 1927- 1930 ,(1989) , 10.1016/S0040-4039(00)99616-3

Julian Adams, Mark Behnke, Shaowu Chen, Amy A. Cruickshank, Lawrence R. Dick, Louis Grenier, Janice M. Klunder, Yu-Ting Ma, Louis Plamondon, Ross L. Stein, Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids Bioorganic & Medicinal Chemistry Letters. ,vol. 8, pp. 333- 338 ,(1998) , 10.1016/S0960-894X(98)00029-8

Mark J. Williamson, Matthew D. Silva, Jennifer Terkelsen, Robbie Robertson, Li Yu, Cindy Xia, Panos Hatsis, Bret Bannerman, Trisha Babcock, Yueying Cao, Erik Kupperman, The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models Molecular Cancer Therapeutics. ,vol. 8, pp. 3234- 3243 ,(2009) , 10.1158/1535-7163.MCT-09-0239

Paul G Richardson, A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opinion on Pharmacotherapy. ,vol. 5, pp. 1321- 1331 ,(2004) , 10.1517/14656566.5.6.1321